Correlation between hepatic levels of MMP activity versus liver RECK, TIMPs and iNOS in the I/R groups. by Andrea Ferrigno (4779078)

Subjects: “…hepatic matrix metalloproteinases a...…”

Hepatic RECK localization at the end of reperfusion. by Andrea Ferrigno (4779078)

Subjects: “…hepatic matrix metalloproteinases a...…”

Correlation between biliary levels of MMPs versus biliary enzymes, glucose and ADMA in the I/R groups. by Andrea Ferrigno (4779078)

Subjects: “…hepatic matrix metalloproteinases a...…”

MMP-2 and MMP-9 activity, LDH, γGT and glucose levels were evaluated in bile at the end of reperfusion period. by Andrea Ferrigno (4779078)

Subjects: “…hepatic matrix metalloproteinases a...…”

Effects of OCA on serum biochemical parameters and MMP activity in sham-operated and I/R rats. by Andrea Ferrigno (4779078)

Subjects: “…hepatic matrix metalloproteinases a...…”

Schematic representation of changes in ADMA, iNOS and MMP pathway that occur in rat livers after I/R (vehicle) or I/R and OCA administration. by Andrea Ferrigno (4779078)

Subjects: “…hepatic matrix metalloproteinases a...…”

Amount of biliary structures and hepatic progenitor cells (HPCs) following I/R. by Andrea Ferrigno (4779078)

Subjects: “…hepatic matrix metalloproteinases a...…”

Hepatic MMP-2 and MMP-9 activity, RECK, TIMP-1 and TIMP-2 at the end of reperfusion. by Andrea Ferrigno (4779078)

Subjects: “…hepatic matrix metalloproteinases a...…”

S1 Fig - by Andrea Ferrigno (4779078)

Subjects: “…hepatic matrix metalloproteinases a...…”

Cell proliferation (p-p42/44 MAPK) and apoptosis (cleaved Caspase-3) following I/R. by Andrea Ferrigno (4779078)

Subjects: “…hepatic matrix metalloproteinases a...…”

Sizes and neuropil structure of gnathal neuromeres. by Christof Rickert (4836519)

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

In house finch Harderian glands, we identified ˜90% fewer differentially expressed genes when comparing non-infected controls to MG-infected birds from populations that are more to... by Amberleigh E. Henschen (3257235)